Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.28 USD | +0.59% | +9.97% | -20.76% |
May. 31 | Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema | MT |
May. 31 | Transcript : Ionis Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.76% | 5.84B | |
+52.99% | 55.7B | |
+40.26% | 39.91B | |
-6.79% | 39.57B | |
-6.65% | 28.16B | |
+14.55% | 26.3B | |
-20.36% | 18.94B | |
+30.61% | 12.17B | |
+26.52% | 12.12B | |
+0.16% | 12.12B |
- Stock Market
- Equities
- IONS Stock
- News Ionis Pharmaceuticals, Inc.
- Morgan Stanley Adjusts Price Target on Ionis Pharmaceuticals to $45 From $42, Maintains Equalweight Rating